Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021 Read more about Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021
Bone Therapeutics Provides First Quarter 2020 Business Update Read more about Bone Therapeutics Provides First Quarter 2020 Business Update
Bone Therapeutics secures EUR 11.0 million financing Read more about Bone Therapeutics secures EUR 11.0 million financing
Bone Therapeutics: Information on the total number of voting rights and shares (March 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (March 2020)
Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer Read more about Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates Read more about Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
Bone Therapeutics announces 2019 full year results Read more about Bone Therapeutics announces 2019 full year results
Bone Therapeutics: Information on the total number of voting rights and shares (February 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (February 2020)
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS Read more about Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS
Bone Therapeutics: Information on the total number of voting rights and shares (January 2020) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (January 2020)
